The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

In a country where chronic skin diseases affect millions, one institution is rewriting the rulebook. Kayakalp Global, based ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

Q: I am a healthy 23-year-old woman. I started noticing extra hairs in my brush, and then my mom found two bald spots on the ...

Analysts anticipate Roivant Sciences to report an earnings per share (EPS) of $-0.16. The announcement from Roivant Sciences is eagerly anticipated, with investors seeking news of surpassing estimates ...

On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Emerging evidence indicates that visceral adiposity, particularly fat accumulation in the abdominal region, is a significant ...

We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

A salty snack may seem harmless, but scientists are learning it can do more than raise your blood pressure. It might also ...

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and gastrointestinal conditions.

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...